Oricell Therapeutics and Umoja Biopharma Announce Strategic Collaboration to Co-Develop Next-Generation In Vivo CAR-T Cell Therapies

Global pioneer in innovative tumor immunotherapy, Oricell Therapeutics (“Oricell”), and global leader in in vivo CAR-T therapy, Umoja Biopharma (“Umoja”), today jointly announced a strategic partnership. The two companies will collaborate to develop novel CAR-T cell therapies for multiple indications, delivering highly effective, convenient, and accessible treatment solutions to patients worldwide.

Under the agreement, both parties will fully leverage their respective technical advantages and harness platform synergies to jointly develop next-generation in vivo CAR-T therapies across multiple global regions. Umoja brings its globally innovative VivoVec™ platform and GMP-compliant manufacturing processes, a technology that enables the direct generation of CAR-T cells within patients’ bodies, offering a more convenient and efficient treatment option. Origincell will contribute its core technologies accumulated over many years in antibody discovery and CAR structure design, which have demonstrated best-in-class efficacy and safety clinical data globally in its tumor immunotherapy products Ori-C101 and OriCAR-017. This collaboration will create a multiplier effect for both parties’ technological platforms, accelerating the development of next-generation in vivo CAR-T therapies.

Umoja Biopharma, Inc. is a clinical-stage biotechnology company focused on developing innovative in vivo cell therapies, dedicated to enhancing the accessibility and efficacy of CAR-T cell therapies in oncology and autoimmune diseases. Leveraging its globally leading VivoVec™ in vivo gene delivery technology, the company enables patients’ own bodies to produce CAR-T cells, providing efficient and convenient cell therapy solutions. Its core technology is supported by an advanced lentiviral vector development and manufacturing base established in Colorado, USA, along with GMP-compliant manufacturing processes, ensuring high product quality and safety.

Yuanqi Biopharma is a clinical-stage biotechnology company committed to becoming an innovation-driven, globally leading pioneer in tumor immunotherapy, aiming to address unmet clinical needs in the fields of oncology and immunology worldwide. Leveraging its independently developed Ori®Ab antibody screening and engineering platform, Ori^®Leveraging its CAR structural platform and specialized expertise accumulated in the field of CMC, Origin Biologics has developed a diverse pipeline of therapeutic candidates for solid tumors and hematologic malignancies. These candidates have demonstrated best-in-class safety and efficacy in clinical studies. Relevant clinical data have been presented at major international conferences, including ASCO 2021, ASCO 2022, EHA 2022, ASCO 2024, SITC 2024, ASH 2024, AACR 2025, and ASCO 2025, and published in prestigious international academic journals such as The Lancet Haematology. Origin Biologics remains committed to advancing the field of cell therapy through innovative technologies, bringing new hope to patients.

Forward-Looking Statements

This press release contains “forward-looking statements” that are not historical facts but constitute predictions of future events based on the beliefs, assumptions, and information currently available to the management of Oricell Therapeutics Holdings Limited (the “Company”). Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause the Company’s actual results, performance, or achievements, or industry results, to differ materially from any future results, performance, or achievements expressed or implied by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date of this press release. The Company expressly states that this press announcement is intended to disclose information regarding clinical progress in research and development, is provided solely for the reference of healthcare professionals, is not for advertising purposes, and the Company does not recommend the use of any unapproved drugs or indications.